Delphi Genetics SA (“Delphi”) has recently sealed a deal with MSD, a subsidiary of Merck & Co (New Jersey, USA) granting a broad-based licensing agreement for the use of the StabyExpress™ technology. The innovative technology offers a high yield, cost efficient alternative to the traditional use of antibiotics for any industrial protein production process involving bacterial fermentation. 

According to the agreement, Merck-MSD will acquire a non-exclusive license to use the StabyExpress™ technology for protein expression in research and product development. Delphi, in return, will be eligible to receive milestone payments based on innovative technologies related to the development of those Merck-MSD products that use the StabyExpress™, as well as royalties on the sales of such products. The endorsement of such a non-exclusive agreement will enable Delphi the opportunity to develop similar strategic collaborations with a broader spectrum of partners, including partners outside biopharma production. For Delphi Genetics, this is their first broad-based licensing agreement that embraces the potential use of the StabyExpress™ technology for protein-based products in both human and animal health sectors. Furthermore, the patented StabyExpress™ technology is already in line with the recommendations of the FDA and the EMA for both human and veterinary uses.

Since it’s inception in 2001, this is Delphi’s third licensing agreement involving a world leading healthcare company. Prior agreements comprise licensing with Sanofi-Pasteur (June 2009) and GSK (September 2010).

Sources:

http://www.delphigenetics.com/news-127.html

Contact:

Delphi Genetics SA
Rue Antoine de Saint Exupéry, 5
B-6041 Charleroi (Gosselies) Belgium

Tel:
Fax:
www.delphigenetics.com

Guy Hélin
e-mail: Tel:

Cédric Szpirer
e-mail: Tel: